Maximilian Stahl1, Aaron D Goldberg2. 1. Department of Medicine, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2. Department of Medicine, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA. goldbera@mskcc.org.
Abstract
PURPOSE OF REVIEW: Immune checkpoint therapy has dramatically changed the therapeutic landscape of solid malignancies. Here, we review the scientific rationale and current data evaluating immune checkpoint inhibitors in acute myeloid leukemia (AML). RECENT FINDINGS: Immune checkpoint inhibitor monotherapy has shown limited clinical activity in AML. Initial results from early-phase clinical trials suggest that rational combinations of immune checkpoint inhibition with hypomethylating agents (HMAs) are safe and potentially more promising. There are currently no data directly comparing immune checkpoint inhibition to standard therapies. Emerging immune targets more specific for leukemia cells including LILRB4 may improve future therapeutic efficacy. The success of immune checkpoint inhibition in AML has been modest to date. However, an improved understanding of the biology and the use of rational combinations has potential to improve rates of durable responses. Multiple clinical trials in AML are currently evaluating the use of immune checkpoints alone and in combination.
PURPOSE OF REVIEW: Immune checkpoint therapy has dramatically changed the therapeutic landscape of solid malignancies. Here, we review the scientific rationale and current data evaluating immune checkpoint inhibitors in acute myeloid leukemia (AML). RECENT FINDINGS: Immune checkpoint inhibitor monotherapy has shown limited clinical activity in AML. Initial results from early-phase clinical trials suggest that rational combinations of immune checkpoint inhibition with hypomethylating agents (HMAs) are safe and potentially more promising. There are currently no data directly comparing immune checkpoint inhibition to standard therapies. Emerging immune targets more specific for leukemia cells including LILRB4 may improve future therapeutic efficacy. The success of immune checkpoint inhibition in AML has been modest to date. However, an improved understanding of the biology and the use of rational combinations has potential to improve rates of durable responses. Multiple clinical trials in AML are currently evaluating the use of immune checkpoints alone and in combination.
Authors: Oliver Goodyear; Angelo Agathanggelou; Igor Novitzky-Basso; Shamyla Siddique; Tina McSkeane; Gordon Ryan; Paresh Vyas; Jamie Cavenagh; Tanja Stankovic; Paul Moss; Charles Craddock Journal: Blood Date: 2010-06-08 Impact factor: 22.113
Authors: Michel Obeid; Antoine Tesniere; François Ghiringhelli; Gian Maria Fimia; Lionel Apetoh; Jean-Luc Perfettini; Maria Castedo; Grégoire Mignot; Theoharis Panaretakis; Noelia Casares; Didier Métivier; Nathanael Larochette; Peter van Endert; Fabiola Ciccosanti; Mauro Piacentini; Laurence Zitvogel; Guido Kroemer Journal: Nat Med Date: 2006-12-24 Impact factor: 53.440
Authors: Noura M El Kholy; Maha M Sallam; Manal B Ahmed; Reem M Sallam; Inas A Asfour; Jehad A Hammouda; Haidy Z Habib; Fatima Abu-Zahra Journal: Med Oncol Date: 2010-03-19 Impact factor: 3.064
Authors: Hartmut Döhner; Elihu H Estey; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Alan K Burnett; Hervé Dombret; Pierre Fenaux; David Grimwade; Richard A Larson; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel A Sanz; Jorge Sierra; Martin S Tallman; Bob Löwenberg; Clara D Bloomfield Journal: Blood Date: 2009-10-30 Impact factor: 22.113
Authors: Christian Blank; Ian Brown; Amy C Peterson; Mike Spiotto; Yoshiko Iwai; Tasuku Honjo; Thomas F Gajewski Journal: Cancer Res Date: 2004-02-01 Impact factor: 12.701
Authors: Rui Su; Lei Dong; Yangchan Li; Min Gao; Li Han; Mark Wunderlich; Xiaolan Deng; Hongzhi Li; Yue Huang; Lei Gao; Chenying Li; Zhicong Zhao; Sean Robinson; Brandon Tan; Ying Qing; Xi Qin; Emily Prince; Jun Xie; Hanjun Qin; Wei Li; Chao Shen; Jie Sun; Prakash Kulkarni; Hengyou Weng; Huilin Huang; Zhenhua Chen; Bin Zhang; Xiwei Wu; Mark J Olsen; Markus Müschen; Guido Marcucci; Ravi Salgia; Ling Li; Amir T Fathi; Zejuan Li; James C Mulloy; Minjie Wei; David Horne; Jianjun Chen Journal: Cancer Cell Date: 2020-06-11 Impact factor: 38.585